ATE251467T1 - Proteinformulierung, die koajulationsfehler viii oder ix in einer saccharose wässriger lösung enthält - Google Patents

Proteinformulierung, die koajulationsfehler viii oder ix in einer saccharose wässriger lösung enthält

Info

Publication number
ATE251467T1
ATE251467T1 AT96909444T AT96909444T ATE251467T1 AT E251467 T1 ATE251467 T1 AT E251467T1 AT 96909444 T AT96909444 T AT 96909444T AT 96909444 T AT96909444 T AT 96909444T AT E251467 T1 ATE251467 T1 AT E251467T1
Authority
AT
Austria
Prior art keywords
solution
aqueous solution
pct
viii
concentration
Prior art date
Application number
AT96909444T
Other languages
English (en)
Inventor
Thomas Oesterberg
Angelica Fatouros
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Application granted granted Critical
Publication of ATE251467T1 publication Critical patent/ATE251467T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT96909444T 1995-03-31 1996-03-29 Proteinformulierung, die koajulationsfehler viii oder ix in einer saccharose wässriger lösung enthält ATE251467T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9501189A SE9501189D0 (sv) 1995-03-31 1995-03-31 Protein formulation
PCT/SE1996/000419 WO1996030041A1 (en) 1995-03-31 1996-03-29 Protein formulation comprising coagulation factor viii or factor ix in an aqueous solution

Publications (1)

Publication Number Publication Date
ATE251467T1 true ATE251467T1 (de) 2003-10-15

Family

ID=20397788

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96909444T ATE251467T1 (de) 1995-03-31 1996-03-29 Proteinformulierung, die koajulationsfehler viii oder ix in einer saccharose wässriger lösung enthält

Country Status (14)

Country Link
US (1) US5919908A (de)
EP (1) EP0819010B1 (de)
JP (1) JP3953102B2 (de)
AT (1) ATE251467T1 (de)
AU (1) AU709642B2 (de)
BR (1) BR9607922A (de)
CA (1) CA2216098C (de)
DE (1) DE69630291T2 (de)
DK (1) DK0819010T3 (de)
ES (1) ES2208736T3 (de)
NZ (1) NZ305028A (de)
PT (1) PT819010E (de)
SE (1) SE9501189D0 (de)
WO (1) WO1996030041A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
DK1820516T3 (da) * 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
MXPA02000525A (es) * 1999-07-15 2005-07-01 Inst Genetics Llc Formulaciones de il-11.
EP2320661B8 (de) * 2001-11-29 2015-09-02 Godo Kaisha IP Bridge 1 Entfernungsverfahren für die Codierungsverzerrung
AU2003247793A1 (en) * 2002-06-26 2004-01-19 Pharmacia Corporation Stable liquid parenteral parecoxib formulation
DE10261126A1 (de) 2002-08-13 2004-03-04 Aventis Behring Gmbh Lagerungsstabile, flüssige Fibrinogen-Formulierung
DE602004019761D1 (de) * 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
CN1767815A (zh) * 2003-03-31 2006-05-03 阿尔萨公司 非水单相载体和使用这类载体的制剂
ES2229931B1 (es) * 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
WO2007044700A2 (en) * 2005-10-07 2007-04-19 Board Of Trustees Of Southern Illinois University Protectant combinations for reducing toxicities
BRPI0821591A2 (pt) * 2007-12-21 2016-05-03 Inspiration Biopharmaceuticals Inc composição liofilizada e métodos de preparação de composição seca estável do fator ix e de liofilização de formulação farmacêutica
EP2113564A1 (de) 2008-05-01 2009-11-04 Arecor Limited Proteinformulierung
MX2011001624A (es) 2008-08-21 2011-03-28 Octapharma Ag Factor viii y ix humano producido en forma recombinante.
MX339060B (es) 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.
GB0915480D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
GB0915481D0 (en) * 2009-09-04 2009-10-07 Arecor Ltd Stable manufacture of factor V111
EP2538967A1 (de) * 2010-02-24 2013-01-02 Arecor Limited Stabile zusammensetzungen für faktor ix
EP2361636A1 (de) 2010-02-26 2011-08-31 CSL Behring AG Immunglobulinpräparat und Aufbewahrungssystem für ein Immunglobulinpräparat
JP2019043961A (ja) * 2010-04-20 2019-03-22 オクタファルマ・アーゲー 医薬タンパク質の新規な安定化剤
CA2796729C (en) * 2010-04-20 2020-06-23 Octapharma Ag Melezitose for stabilizing human blood plasma proteins
CN106687126B (zh) 2014-08-04 2020-07-28 杰特有限公司 因子viii制剂
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
JP2025512143A (ja) 2020-11-09 2025-04-17 武田薬品工業株式会社 酸化ケイ素吸着を使用する血漿からのｆｖｉｉｉの精製

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
US4447416A (en) * 1982-04-28 1984-05-08 American National Red Cross Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
JPS59134730A (ja) * 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
JPH0779694B2 (ja) * 1985-07-09 1995-08-30 カドラント バイオリソ−シズ リミテツド 蛋白質および同類品の保護
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
FR2687317B1 (fr) * 1992-02-13 1995-06-23 Aetsrn Composition pour stabiliser le plasma sanguin en cour de pasteurisation et solution plasmatique pasteurisee a usage therapeutique.
DE4205192C2 (de) * 1992-02-20 1995-10-12 Euka Bauelemente Verkaufsgesel Bahnsteig
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
CN1064552C (zh) * 1993-02-09 2001-04-18 奥克塔法马有限公司 失活无脂质被膜病毒的方法
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency

Also Published As

Publication number Publication date
US5919908A (en) 1999-07-06
AU709642B2 (en) 1999-09-02
EP0819010A1 (de) 1998-01-21
JP3953102B2 (ja) 2007-08-08
PT819010E (pt) 2004-01-30
DK0819010T3 (da) 2004-02-09
CA2216098C (en) 2011-08-23
NZ305028A (en) 1998-08-26
CA2216098A1 (en) 1996-10-03
WO1996030041A1 (en) 1996-10-03
JPH11502833A (ja) 1999-03-09
EP0819010B1 (de) 2003-10-08
DE69630291D1 (de) 2003-11-13
ES2208736T3 (es) 2004-06-16
BR9607922A (pt) 1998-06-09
AU5293496A (en) 1996-10-16
DE69630291T2 (de) 2004-05-06
SE9501189D0 (sv) 1995-03-31

Similar Documents

Publication Publication Date Title
ATE251467T1 (de) Proteinformulierung, die koajulationsfehler viii oder ix in einer saccharose wässriger lösung enthält
EE03118B1 (et) Proteiinravim ja selle valmistamismeetod
Boright et al. A dissociation between the adrenal and extra-adrenal actions of corticotrophin by periodate oxidation
Clyman et al. Oxygen and cyclic nucleotides in human umbilical artery.
WO1993016719A3 (en) Use of platelet derived growth factor in ophthalmic wound healing
ES2150940T3 (es) Formulacion proteinica que comprende hormona del crecimiento.
GR1000869B (el) Νέες συν?έσεις που περιέχουν συνδυασμούς (συζευγμένους εταίρους)υαλουρονικού οξέος και μέ?οδος για την παρασκευή τους.
Weary Pityrosporum ovale: observations on some aspects of host-parasite interrelationship
DE69025920D1 (de) Glykosaminoglykan-modifiertes Protein, Verfahren zu dessen Herstellung und pharmazeutische Zubereitungen, die es enthalten
MY104412A (en) Acne treatment.
DE3775960D1 (de) Pharmazeutische zubereitung sowie verfahren zur herstellung derselben.
EP0070992B1 (de) Verfahren zur Stabilisierung von Peroxidase in einem flüssigen Medium und so stabilisiertes Medium
Shackney et al. Stimulation of glucose metabolism in brown adipose tissue by addition of insulin in vitro
ATE205399T1 (de) Eine lagerstabile wässrige lösung zur infusion die einen thrombininhibitor enthält
CA2067371A1 (en) Stable hemoglobin based composition and method to store same
Hall et al. The oxidation of serum sulph-hydryl groups by hydrogen peroxide secreted by stimulated phagocytic cells in rheumatoid arthritis
Martius Mode of action of vitamins K in animals
AU7252581A (en) Salt of furosemide or piretanide as acid component and penbutolol or (-)-3-(4-3-(3,4-dimethoxyphenylethylamino)-2- hydroxypropoxy)-phenyl)-crotonitrile as base component
Hirai et al. Varied cytochrome oxidase activities of the alveolar type I, type II and type III cells in rat lungs: quantitative cytochemistry
DE2338970A1 (de) Verfahren zur herstellung standardisierter, stabilisierter, wasserloeslicher placenta-extrakte
Bertolami et al. The effect of skin grafting upon prolyl hydroxylase and hyaluronidase activities in mammalian wound repair
SE9402119D0 (sv) Solution
Pitaru et al. The effects of partial demineralization and fibronectin on migration and growth of gingival epithelial cells on cementum in vitro
Isaac et al. Differences in placebo effects
Levy et al. Effects of inflammation on proteins and enzymes in rat plasma

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0819010

Country of ref document: EP